• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vor Biopharma Inc (NQ: VOR )

    1.190 -0.010 (-0.83%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 313,235
    Open 1.200
    Bid (Size) 1.160 (2)
    Ask (Size) 1.220 (9)
    Prev. Close 1.200
    Today's Range 1.165 - 1.225
    52wk Range 1.110 - 4.785
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    VOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024
    VOR stock results show that Vor Biopharma beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -46.64%
    -46.64%
    1 Month
    -26.09%
    -26.09%
    3 Month
    -41.67%
    -41.67%
    6 Month
    -52.59%
    -52.59%
    1 Year
    -72.39%
    -72.39%

    More News

    Read More
    Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in Upcoming Investor Conferences
    From Vor Biopharma
    Via GlobeNewswire
    Vor Biopharma: Q4 Earnings Insights
    Via Benzinga
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
    From Vor Biopharma
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Vor Bio to Participate in Upcoming Investor Conferences
    From Vor Biopharma
    Via GlobeNewswire
    The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
    Via InvestorPlace
    VOR Stock Earnings: Vor Biopharma Beats EPS for Q4 2023
    Via InvestorPlace
    Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in Upcoming Investor Conferences
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in Upcoming Investor Conferences
    From Vor Biopharma
    Via GlobeNewswire
    Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
    From Vor Biopharma
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.